SOPHiA GENETICS Touts Growth, 315K+ Analyses at J.P. Morgan Conf.
Ticker: SOPH · Form: 6-K · Filed: 2024-01-10T00:00:00.000Z
Sentiment: bullish
Topics: corporate-update, growth-strategy, partnerships, conference-presentation
TL;DR
**SOPH is growing fast, hitting 315k+ analyses in 2023 and landing new big partners!**
AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) is highlighting its near-term growth strategy at the 42nd annual J.P. Morgan Healthcare Conference on January 11, 2024. The company announced strong adoption of its SOPHiA DDM™ Platform, leading to a record 315,000+ analyses globally in 2023, and new partnerships with Tennessee Oncology, Dasa, and The Royal Marsden for liquid biopsy and HRD. This matters to investors because it demonstrates continued operational growth and expanding market penetration, which could drive future revenue and stock performance.
Why It Matters
This filing indicates SOPHiA GENETICS is successfully expanding its platform's reach and analysis volume, suggesting a positive trajectory for its core business and potential for increased revenue.
Risk Assessment
Risk Level: low — The filing primarily communicates positive business updates and growth, indicating low immediate risk.
Analyst Insight
A smart investor would view this as positive news, indicating strong operational momentum and market adoption. It might be a good time to research SOPH further or consider adding to a position, especially if the stock reacts positively to the J.P. Morgan presentation.
Key Numbers
- 315,000+ — analyses globally (record analysis volume for the full year of 2023 on the SOPHiA DDM™ Platform)
- 42nd — annual conference (the J.P. Morgan Healthcare Conference where SOPHiA GENETICS is presenting)
- January 11, 2024 — presentation date (when SOPHiA GENETICS will present at the conference)
- 9:00 a.m. PST — presentation time (when SOPHiA GENETICS will present at the conference)
Key Players & Entities
- SOPHiA GENETICS SA (company) — the registrant and presenter
- Daan van Well (person) — Chief Legal Officer who signed the filing
- J.P. Morgan Healthcare Conference (event) — where SOPHiA GENETICS is presenting its strategy
- Tennessee Oncology (company) — new partner for liquid biopsy and HRD
- Dasa (company) — new partner for liquid biopsy and HRD
- The Royal Marsden (company) — new partner for liquid biopsy and HRD
Forward-Looking Statements
- SOPHiA GENETICS will report strong Q4 2023 and full-year 2023 financial results, driven by the increased analysis volume. (SOPHiA GENETICS SA) — medium confidence, target: Q1 2024 (next earnings report)
- The new partnerships with Tennessee Oncology, Dasa, and The Royal Marsden will contribute to accelerated revenue growth in 2024. (SOPHiA GENETICS SA) — medium confidence, target: End of 2024
FAQ
What is the primary purpose of this 6-K filing by SOPHiA GENETICS SA?
The primary purpose of this 6-K filing is to report that SOPHiA GENETICS SA will be highlighting its near-term growth strategy at the 42nd annual J.P. Morgan Healthcare Conference on January 11, 2024, and to include the related press release and informative slides as exhibits.
What significant operational milestone did SOPHiA GENETICS achieve in 2023?
SOPHiA GENETICS achieved a record of over 315,000 analyses globally for the full year of 2023, demonstrating continued adoption of its SOPHiA DDM™ Platform in clinical markets.
Which new partners did SOPHiA GENETICS announce in relation to its liquid biopsy and HRD offerings?
SOPHiA GENETICS announced new partnerships with Tennessee Oncology, Dasa, and The Royal Marsden for liquid biopsy and HRD on its SOPHiA DDM™ Platform.
Who signed this 6-K filing on behalf of SOPHiA GENETICS SA and what is their title?
The 6-K filing was signed by Daan van Well, who holds the title of Chief Legal Officer for SOPHiA GENETICS SA, on January 10, 2024.
What specific exhibits are included with this 6-K filing?
This 6-K filing includes two exhibits: Exhibit 99.1, which is the Press Release for the J.P. Morgan Health Care Conference dated January 11, 2024, and Exhibit 99.2, which consists of Informative slides for SOPHiA GENETICS for the J.P. Morgan Health Care Conference, also dated January 11, 2024.
Filing Stats: 171 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-01-10 16:59:46
Filing Documents
- dp205124_6k.htm (6-K) — 10KB
- dp205124_ex9901.htm (EX-99.1) — 33KB
- dp205124_ex9902.htm (EX-99.2) — 30KB
- image_001.jpg (GRAPHIC) — 4KB
- image_002.jpg (GRAPHIC) — 209KB
- image_003.jpg (GRAPHIC) — 724KB
- image_004.jpg (GRAPHIC) — 379KB
- image_005.jpg (GRAPHIC) — 380KB
- image_006.jpg (GRAPHIC) — 297KB
- image_007.jpg (GRAPHIC) — 337KB
- image_008.jpg (GRAPHIC) — 334KB
- image_009.jpg (GRAPHIC) — 341KB
- image_010.jpg (GRAPHIC) — 305KB
- image_011.jpg (GRAPHIC) — 319KB
- image_012.jpg (GRAPHIC) — 214KB
- image_013.jpg (GRAPHIC) — 363KB
- image_014.jpg (GRAPHIC) — 332KB
- image_015.jpg (GRAPHIC) — 249KB
- image_016.jpg (GRAPHIC) — 254KB
- image_017.jpg (GRAPHIC) — 202KB
- image_018.jpg (GRAPHIC) — 363KB
- image_019.jpg (GRAPHIC) — 270KB
- image_020.jpg (GRAPHIC) — 243KB
- image_021.jpg (GRAPHIC) — 221KB
- image_022.jpg (GRAPHIC) — 334KB
- image_023.jpg (GRAPHIC) — 323KB
- image_024.jpg (GRAPHIC) — 723KB
- image_025.jpg (GRAPHIC) — 620KB
- 0000950103-24-000536.txt ( ) — 11563KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SOPHiA GENETICS SA Date: January 10, 2024 By: /s/ Daan van Well Name: Daan van Well Title: Chief Legal Officer EXHIBIT INDEX Exhibit No. Description 99.1 Press Release for JP Morgan Health Care Conference, dated January 11, 2024 99.2 Informative slides SOPHiA GENETICS for JP Morgan Health Care Conference, dated January 11, 2024